# Sermorelin Dosage in the Research Literature > Sermorelin dosage as documented in studies: pediatric 30 mcg/kg/day, older-men 0.5-1 mg twice daily for 14 days, and IV pharmacokinetic doses of 0.25-2 mcg/kg. Studied-at framing only, every figure cited. What was administered, to which species, by which route — reported as studied figures, never as human guidance. ## The short version This page reports the sermorelin dosage figures that appear in published studies, and nothing more. It does not tell anyone how to use sermorelin. In a children's growth study, the dose was 30 micrograms per kilogram of body weight per day, given as a bedtime injection under the skin. In an aging study, older men received 0.5 mg or 1 mg twice a day for 14 days. In a pharmacology study, IV doses of 0.25 to 2 micrograms per kilogram set off growth-hormone release. These are the numbers researchers used in those specific studies, each cited below — not a recommendation for any person. ## Doses used in the research literature These are the sermorelin doses recorded in the published literature, presented as studied figures only. In the pediatric GH-deficiency efficacy program, 30 mcg/kg/day was administered subcutaneously at bedtime [2]. In aging research in older men, 0.5 mg and 1 mg were given subcutaneously twice daily for 14 days, producing dose-related GH and IGF-1 increases [3]. In pharmacokinetic work, intravenous doses of 0.25-2 mcg/kg elicited GH release in healthy men, with maximal release at 1-2 mcg/kg [5]. A single intravenous bolus (historically around 1 mcg/kg) was also used diagnostically to test pituitary GH reserve [5]. Every figure above describes what was administered, to which population, by which route, in a specific study. None of it is a dose recommendation for any individual. ## Routes studied and what each implies Subcutaneous injection was the primary route in efficacy research, used in both the pediatric growth program and the older-men aging study [2][3]. Intravenous dosing appeared mainly in diagnostic and pharmacokinetic studies, where rapid, controlled delivery suited the measurement [5]. The intranasal route was examined historically but showed bioavailability of only about 3-5%, and a pediatric intranasal trial reported declining absorption, antibody formation, and no height-velocity gain over 6 months [14]; see [sermorelin half-life and pharmacokinetics](/half-life). Because GHRH(1-29) clears in minutes [5], research protocols that aimed to sustain a GH-axis effect dosed frequently or at bedtime to align with the nocturnal GH pulse — a description of study design, not a protocol to follow [8]. ## The diagnostic GHRH stimulation context One historical use of GHRH(1-29) was diagnostic rather than therapeutic. A single intravenous bolus — commonly around 1 mcg/kg — was used as a GH stimulation test: a procedure in which a GH secretagogue is given to assess the pituitary's capacity to release growth hormone [5]. The pharmacokinetic study underpins those figures, showing GH release from doses as low as 0.25 mcg/kg and maximal release at 1-2 mcg/kg IV [5]. That diagnostic framing is worth separating from anti-aging dosing claims. A bolus given once to probe pituitary reserve is a measurement, not a treatment regimen, and it tells you about the gland's responsiveness rather than about any long-term effect [5]. The studied doses on this page span three distinct purposes — pediatric growth, adult aging research, and pituitary diagnostics — and conflating them is a common source of the overstatement the literature warns about [6]. ## How the studied doses map to the findings Each studied sermorelin dose belongs to a specific question, and reading them that way prevents over-generalization. The 30 mcg/kg/day bedtime subcutaneous regimen was a pediatric growth-deficiency dose, and the outcome it produced was a first-year height-velocity rise from about 4.1 to roughly 7-8 cm/year [2]. The 0.5 mg and 1 mg twice-daily subcutaneous regimen for 14 days was an adult aging-research dose, and it produced dose-related GH and IGF-1 increases, with the high dose returning those measures to a young-adult range [3]. The intravenous 0.25-2 mcg/kg figures were pharmacokinetic and diagnostic, chosen to characterize GH release and pituitary reserve rather than to treat anything [5]. A dose that accelerates growth in a deficient child is not a template for an adult, and a diagnostic IV bolus is not a maintenance regimen — the figures describe distinct experiments. Reported tolerability across these doses is summarized in [sermorelin side effects in the literature](/side-effects). ## Reconstitution and stability in study handling Lyophilized sermorelin acetate is reconstituted with sterile diluent and, once reconstituted, typically refrigerated [10]. Aqueous peptide solutions are susceptible to degradation, which is why GHRH(1-29) is supplied as a lyophilized powder rather than a ready solution [10]. Compounded preparations are prepared under USP <797> sterile-compounding standards [10]. These handling notes describe how the peptide is kept stable for study, not how anyone should prepare or use it. The half-life and route figures on this page are pharmacologic descriptions; the dose figures are the doses specific studies administered. Read together with [the aging GH/IGF-1 axis research](/research), they describe a precisely characterized short-term pharmacology with limited long-term adult data [6]. --- A frosted-glass reading of the sermorelin record — each GHRH(1-29) figure floated in its own panel and carried back to its study, the reported effects framed plainly beside where the long-term adult data genuinely thin, and the body-composition findings marked as tesamorelin where they belong; no clinic behind the glass and nothing here compounded, dosed, prescribed, or sold.